Femasys/$FEMY
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Femasys
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Ticker
$FEMY
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
70
ISIN
US31447E1055
Website
Femasys Metrics
BasicAdvanced
$30M
-
-$0.91
-2.61
-
Price and volume
Market cap
$30M
Beta
-2.61
52-week high
$1.76
52-week low
$0.69
Average daily volume
423K
Financial strength
Current ratio
0.928
Quick ratio
0.412
Long term debt to equity
69.756
Total debt to equity
383.926
Interest coverage (TTM)
-11.63%
Profitability
EBITDA (TTM)
-19.473
Gross margin (TTM)
66.24%
Net profit margin (TTM)
-1,242.56%
Operating margin (TTM)
-1,164.30%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-65.69%
Return on equity (TTM)
-239.87%
Valuation
Price to revenue (TTM)
12.667
Price to book
12.63
Price to tangible book (TTM)
13.02
Price to free cash flow (TTM)
-1.05
Free cash flow yield (TTM)
-95.22%
Free cash flow per share (TTM)
-88.68%
Growth
Revenue change (TTM)
61.97%
Earnings per share change (TTM)
9.51%
3-year revenue growth (CAGR)
13.20%
3-year earnings per share growth (CAGR)
0.04%
Femasys News
AllArticlesVideos
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
GlobeNewsWire·3 days ago
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
GlobeNewsWire·1 week ago
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Femasys stock?
Femasys (FEMY) has a market cap of $30M as of July 04, 2025.
What is the P/E ratio for Femasys stock?
The price to earnings (P/E) ratio for Femasys (FEMY) stock is 0 as of July 04, 2025.
Does Femasys stock pay dividends?
No, Femasys (FEMY) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Femasys dividend payment date?
Femasys (FEMY) stock does not pay dividends to its shareholders.
What is the beta indicator for Femasys?
Femasys (FEMY) has a beta rating of -2.61. This means that it has an inverse relation to market volatility.